ArticleExperimental & molecular medicine2025
Dynamics of chromatin accessibility governing Gd-IgA1 synthesis in B cells associated with IgA nephropathy.
Article in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Identification of key genes related to arginine metabolism in immunoglobulin A nephropathy through the combination of scRNA-seq and bulk RNA-seq data.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. B cells are believed to play a central role in the pathogenesis of IgAN by producing galactose-deficient IgA1 (Gd-IgA1), partly due to aberrant gene expression in B cells. However, the mechanisms underlying the abnormal gene expression in B cells derived from patients with IgAN remain elusive. Here we unveil a broad spectrum of variations in chromatin accessibility in B cells of patients with IgAN through an assay for transposase-accessible chromatin using sequencing (ATAC-seq) by evaluating active DNA regulatory components. A total of 629 genes showed transcriptional alterations associated with differentially chromatin accessibility. The degree of chromatin accessibility was associated with gene expression in peripheral blood B cells of patients with IgAN. Gene Ontology analysis of genes associated with differentially expressed genes and differentially accessible regions revealed enrichment in pathways related to the regulation of transcription. Furthermore, KLF4 was also identified as a key transcription factor promoting the production of IgA1 and Gd-IgA1. In vitro, knockdown of KLF4 suppressed the production of Gd-IgA1 in IgA-secreting cell lines. Through RNA sequencing, this study further showed that KLF4 could regulate the expression of genes related to the intestinal immune network for IgA production. Chromatin immunoprecipitation sequencing combined with RNA sequencing revealed that KLF4 could bind to the IL-6 promoter and regulate its expression. Mechanistically, a luciferase reporter assay verified that KLF4 directly bound to the cis-regulatory element of IL-6 and promoted its expression. The knockdown of KLF4 was shown to alleviate renal lesions and mesangial hypercellularity in IgAN mice. Collectively, the findings from this study elucidated a chromatin-mediated mechanism underlying the differential responses of B cells in IgAN and identified KLF4 as a potential therapeutic target of IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.